Pharmaron Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
25,088
- Stock Symbol
-
300759
- Investments
-
24
- Share Price
-
$6.36
- (As of Friday Closing)
Pharmaron General Information
Description
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
Contact Information
Website
www.pharmaron.cnCorporate Office
- Number 6, Taihe Road, Yizhuang Economic Development Zone
- Daxing District
- Beijing, 100176
- China
Corporate Office
- Number 6, Taihe Road, Yizhuang Economic Development Zone
- Daxing District
- Beijing, 100176
- China
Pharmaron Stock Performance
As of 13-Nov-2026, Pharmaron’s stock price is $6.36. Its current market cap is $10.7B with 1.84B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.36 | $6.62 | $3.10 - $7.96 | $10.7B | 1.84B | 50.5M | $0.14 |
Pharmaron Financials Summary
As of 30-Sep-2026, Pharmaron has a trailing 12-month revenue of $2.32B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 12,146,206 | 7,426,753 | 6,277,900 | 7,232,018 |
| Revenue | 2,323,159 | 1,960,013 | 1,710,800 | 1,630,840 |
| EBITDA | 330,493 | 451,526 | 461,297 | 411,838 |
| Net Income | 256,809 | 231,376 | 249,928 | 226,307 |
| Total Assets | 4,809,415 | 3,872,366 | 3,277,681 | 3,735,112 |
| Total Debt | 1,113,763 | 1,006,248 | 818,549 | 1,368,054 |
Pharmaron Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pharmaron Comparisons
Industry
Financing
Details
Pharmaron Competitors (39)
One of Pharmaron’s 39 competitors is Syngene International, a Formerly PE-Backed company based in Bangalore, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Syngene International | Formerly PE-Backed | Bangalore, India | ||||
| ChemPartner | Formerly PE-Backed | Shanghai, China | ||||
| Evotec | Formerly PE-Backed | Hamburg, Germany | ||||
| Grifols | Corporation | Barcelona, Spain | ||||
| Techpool | Venture Capital-Backed | Guangzhou, China |
Pharmaron Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Pharmaron Patents
Pharmaron Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026064629-A1 | Improved calmodulin inhibitors and methods of use thereof | Pending | 20-Sep-2024 | ||
| WO-2026060616-A1 | Phenothiazine and phenoxazine calmodulin inhibitors and methods of use thereof | Pending | 20-Sep-2024 | ||
| WO-2025119254-A1 | Method for preparing dihydronaphthalene derivative | Inactive | 06-Dec-2023 | ||
| US-20250034129-A1 | Crystalline forms of (6s,7s)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2h-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione | Pending | 28-Jul-2023 | ||
| US-20250206743-A1 | Tyk2 inhibitor synthesis and intermediates thereof | Pending | 25-Mar-2022 | C07D487/04 |
Pharmaron Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Pharmaron Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Pharmaron Investments & Acquisitions (24)
Pharmaron’s most recent deal was a Merger/Acquisition with Biortus Biosciences for . The deal was made on 28-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Biortus Biosciences | 28-Oct-2025 | Merger/Acquisition | Biotechnology | ||
| Jiying Intelligent (Business/Productivity Software) | 01-Jun-2024 | Merger/Acquisition | Business/Productivity Software | ||
| Kanglong Clinical | 05-Dec-2022 | Corporate | Drug Discovery | ||
| Kanglong Clinical | 18-Nov-2022 | Secondary Transaction - Private | Drug Discovery | ||
| Noramco (API Manufacturing Site in Coventry) | 12-Jul-2022 | Corporate Asset Purchase | Buildings and Property |
Pharmaron ESG
Risk Overview
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Laboratory Equipment and Services
Subindustry
Rank
Percentile
Pharmaron Exits (6)
Pharmaron’s most recent exit was on 19-Nov-2020 from Imago BioSciences. The exit was categorized as with 14 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Imago BioSciences | 19-Nov-2020 | Completed |
|
||
| Zentalis Pharmaceuticals | 09-Dec-2019 | Completed |
|
||
| LinkStart | 29-May-2019 | Completed |
|
||
| Imago BioSciences | 15-Mar-2019 | Completed |
|
||
| Zentalis Pharmaceuticals | 01-Jan-2017 | Early Stage VC | Completed |
|
Pharmaron Affiliates
Subsidiaries (9)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Kanglong Clinical | Chengdu, China | 2021 | |
| Bayland Capital | Beijing, China | 2019 | |
| Jiying Intelligent (Business/Productivity Software) | Shanghai, China | 2018 | |
| Kangruitai Biotechnology | Zhanjiang, China | 2017 | |
| Songqiao Health | Beijing, China | 2014 |
Pharmaron FAQs
-
When was Pharmaron founded?
Pharmaron was founded in 2004.
-
Where is Pharmaron headquartered?
Pharmaron is headquartered in Beijing, China.
-
What is the size of Pharmaron?
Pharmaron has 25,088 total employees.
-
What industry is Pharmaron in?
Pharmaron’s primary industry is Drug Discovery.
-
Is Pharmaron a private or public company?
Pharmaron is a Public company.
-
What is Pharmaron’s stock symbol?
The ticker symbol for Pharmaron is 300759.
-
What is the current stock price of Pharmaron?
As of 13-Nov-2026 the stock price of Pharmaron is $6.36.
-
What is the current market cap of Pharmaron?
The current market capitalization of Pharmaron is $10.7B.
-
What is Pharmaron’s current revenue?
The trailing twelve month revenue for Pharmaron is $2.32B.
-
Who are Pharmaron’s competitors?
Syngene International, ChemPartner, Evotec, Grifols, and Techpool are some of the 39 competitors of Pharmaron.
-
What is Pharmaron’s annual earnings per share (EPS)?
Pharmaron’s EPS for 12 months was $0.14.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
